Expressão imunoistoquímica das proteínas Ciclina D1 e c-MYC em meningiomas intracranianos
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: Meningioma intracraniano é o tumor mais frequente do sistema nervoso central e marcadores imunoistoquímicos são importantes para auxiliar na terapia alvo e prognóstico.
Objetivo: Avaliar a expressão dos marcadores ciclina D1 e c-MYC em meningiomas intracranianos e correlacioná-la com a agressividade e recorrência desses tumores.
Método: Estudo retrospectivo, observacional, transversal utilizando dados dos prontuários de pacientes com diagnóstico de meningioma intracraniano que foram internados e submetidos à ressecção cirúrgica. Os dados epidemiológicos, clínicos e radiológicos foram coletados e anotados. Foi realizada imunoistoquímica para os marcadores ciclina D1 e c-MYC em todas as amostras. Os dados referentes ao grau histológico dos tumores foram cruzados com o resultado obtido pela imunomarcação.
Resultado: Foram incluídos 51 pacientes (72,5% mulheres e 27,5% homens) com média de 53,5 anos. Cefaleia foi o sintoma mais comum e tumores localizados na base do crânio representaram 53% dos casos. Meningiomas grau I foram detectados em 58,8%, grau II em 29,4% e grau III em 9,8%. Recidiva tumoral foi observada em 2 casos (3,9%) e pacientes livres de doença corresponderam a 49%. A média do tempo de seguimento foi de 798 dias (13-2267). A ciclina D1 foi identificada em 100% dos meningiomas e a intensidade de sua expressão foi fraca em 52,4% das lesões grau I, moderada em 50% dos tumores grau II e forte em 100% dos tumores grau III (p<0,001). c-MYC foi identificado em 17,7% (4,7% grau I, 66,7% grau II e 100% grau III) e sua expressão foi fraca em 50% no grau II e moderada em 100% do grau III (p<0,001). A presença dos marcadores não teve relação estatisticamente significativa com o desfecho dos pacientes.
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol. 2018;14(21):2161-77. https://doi.org/10.1080/14737175.2018.1429920.
Wang N, Osswald M. Meningiomas: Overview and New Directions in Therapy. Semin Neurol. 2018;38(1):112-20. https://doi.org/10.1055/s-0038-1636502
Nowosielski M, Galldiks N, Iglseder S, Kickingereder P, Deimling AV, Bendszus M, et al. Diagnostic challenges in meningioma. Neuro Oncol. 2017;19(12):1588-98. https://doi.org/10.1093/neuonc/nox101
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22-39. https://doi.org/10.1136%2Fjnnp.20.1.22
Al-Rashed M, Foshay K, Abedalthagafi M. Recent advances in meningioma immunogenetics. Front Oncol. 2020;9:1472. https://doi.org/10.3389/fonc.2019.01472
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology. 2004;145(12):5439-47. https://doi.org/10.1210/en.2004-0959
Milenković S, Marinkovic T, Jovanovic MB, Djuricic S, Berisavac II, Berisavac I. Cyclin D1 immunoreactivity in meningiomas. Cell Mol Neurobiol. 2008;28(6):907-13. https://doi.org/10.1007/s10571-008-9278-x
Lee SH, Lee YS, Hong YG, Kang CS. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas. Apmis. 2013;122(1):16-24. https://doi.org/10.1111/apm.12079
Trop-Steinberg S, Azar Y. Is Myc an important biomarker? Myc expression in immune disorders and cancer. Am J Med Sci. 2018;355(1):67-75. https://doi.org/10.1016/j.amjms.2017.06.007
Detta A, Kenny BG, Smith C, Logan A, Hitchcock E. Correlation of proto-oncogene expression and proliferation in meningiomas experimental study. Neurosurgery. 1993;33(6):1065-74. https://doi.org/10.1227/00006123-199312000-00015
Kazumoto K, Tamura M, Hoshino H, Yuasa Y. Enhanced expression of the sis and c-myc oncogenes in human meningiomas. J Neurosurg. 1990;72:786-91. https://doi.org/10.3171/jns.1990.72.5.0786
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9)e383-91. https://doi.org/10.1016/s1470-2045(16)30321-7
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1-iv96. https://doi.org/10.1093/neuonc/noaa200
Ongaratti BR, Silva CBO, Trott G, Haag T, Leães CGS, Ferreira NP, et al. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res. 2016;49(4)e5125. https://doi.org/10.1590/1414-431x20155125
Behbahani M, Skeie GO, Eide GE, Hausken A, Lund-Johansen M, Skeie BS. A prospective study of the natural history of incidental meningioma—Hold your horses! Neurooncol Pract. 2019;6(6):438-50. https://doi.org/10.1093/nop/npz011
Wu A, Garcia MA, Magill ST, Chen W, Vasudevan HN, Perry A, et al. Presenting symptoms and prognostic factors for symptomatic outcomes following resection of meningioma. World Neurosurg. 2018;111:e149-59. https://doi.org/10.1016/j.wneu.2017.12.012
Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Bessaoud F, et al. Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. 2018;64(1):15-21. https://doi.org/10.1016/j.neuchi.2014.11.013
Englot DJ, Magill ST, Han SJ, Chang EF, Berger MS, McDermott MW. Seizures in supratentorial meningioma: A systematic review and meta-analysis. J Neurosurg. 2016;124(6):1552-61. https://doi.org/10.3171/2015.4.jns142742
Woehrer A, Hackl M, Waldhör T, Weis S, Pichler J, Olschowski A, et al. Relative survival of patients with non-malignant central nervous system tumours: A descriptive study by the Austrian Brain Tumour Registry. Br J Cancer. 2014;110(2):286-96. https://doi.org/10.1038/bjc.2013.714
Kim D, Niemierko A, Hwang WL, Stemmer-Rachamimov AO, Curry WT, Barker FG, et al. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg. 2018;128(4):1123-32. https://doi.org/10.3171/2016.11.jns16913
Zeybek U, Yaylim I, Ozkan NE, Korkmaz G, Turan S, Kafadar D, et al. Cyclin D1 gene G870A variants and primary brain tumors. Asian Pac J Cancer Prev. 2013;14(7):4101-6. https://doi.org/10.7314/apjcp.2013.14.7.4101
Helseth E, Unsgaard G, Dalen A, Fure H, Skandsen T, Odegaard A, et al. Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumours. Br J Neurosurg. 1988;2(2):217-25. https://doi.org/10.3109/02688698808992672
Kim JH, Lee H, Cho KJ, Jang JJ, Hong SI, Lee JH. Enhanced expression of the c-myc protooncogene in human intracranial meningiomas. J Korean Med Sci. 1993;8(1):68-72. https://doi.org/10.3346/jkms.1993.8.1.68
Ng HK, Chen L. Apoptosis is associated with atypical or malignant change in meningiomas: An in situ labelling and immunohistochemical study. Histopathology. 1998;33(1):64-70. https://doi.org/10.1046/j.1365-2559.1998.00440.x
Jiang J, Song Y, Liu N, Lin C, Zhao S, Sun Y, et al. SPARC and Vav3 expression in meningioma: Factors related to prognosis. Can J Neurol Sci. 2013;40(6):814-8. https://doi.org/10.1017/s0317167100015948
Alama A, Barbieri F, Spaziante R, Bruzzo C, Dadati P, Docaratto A, et al. Significance of cyclin D1 expression in meningiomas: A preliminary study. J Clin Neurosci. 2007;14(4):355-8. https://doi.org/10.1016/j.jocn.2006.04.001
El-Gewely MR, Andreassen M, Walquist M, Ursvik A, Knutsen E, Nystad M, et al. Differentially expressed microRNAs in meningiomas grades I and II suggest shared biomarkers with malignant tumors. Cancers. 2016;8(3):31. https://doi.org/10.3390/cancers8030031
Maxwell M, Galanopoulos T, Antoniades HN. Expression of cyclin D1 proto-oncogene mRNA in primary meningiomas may contribute to tumorigenesis. Int J Oncol. 1996;9(6):1213-7. https://doi.org/10.3892/ijo.9.6.1213
Gauchotte G, Vigouroux C, Rech F, Battaglia-Hsu SF, Soudant M, Pinelli C, et al. Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome. Am J Surg Pathol. 2012;36(2):283-91. https://doi.org/10.1097/pas.0b013e318235ee03
Shivapathasundram G, Wickremesekera AC, Brasch HD, Marsh R, Tan ST, Itinteang T. Expression of embryonic stem cell markers on the microvessels of WHO grade I meningioma. Front Surg. 2018;5:65. https://doi.org/10.3389/fsurg.2018.00065
Nagashima G, Asai J, Suzuki R, Fujimoto T. Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol. 2001;18(1):1-5. https://doi.org/10.1007/bf02478918
Tao Y, Wei Q, Xu Z, Bai Z, Li Y, Luo C, et al. Holistic and network analysis of meningioma pathogenesis and malignancy. Biofactors. 2006;28(3-4):203-19. https://doi.org/10.1002/biof.5520280307
Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyutat J, et al. Expression of c-Myc, neurofibromatosis type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008;27(9):334-45. https://doi.org/10.5414/npp27334